TW201117818A - Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients - Google Patents
Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients Download PDFInfo
- Publication number
- TW201117818A TW201117818A TW099125518A TW99125518A TW201117818A TW 201117818 A TW201117818 A TW 201117818A TW 099125518 A TW099125518 A TW 099125518A TW 99125518 A TW99125518 A TW 99125518A TW 201117818 A TW201117818 A TW 201117818A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- fat
- nutrient
- lactobacillus
- kcal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 50
- 239000006041 probiotic Substances 0.000 title claims abstract description 44
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 44
- 210000000481 breast Anatomy 0.000 title claims abstract description 11
- 235000016709 nutrition Nutrition 0.000 title description 6
- 230000000529 probiotic effect Effects 0.000 claims abstract description 22
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 9
- 235000020256 human milk Nutrition 0.000 claims description 32
- 229920001542 oligosaccharide Polymers 0.000 claims description 23
- 150000002482 oligosaccharides Chemical class 0.000 claims description 23
- 210000004251 human milk Anatomy 0.000 claims description 21
- 235000019197 fats Nutrition 0.000 claims description 20
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 235000021466 carotenoid Nutrition 0.000 claims description 7
- 150000001747 carotenoids Chemical class 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 6
- 208000002881 Colic Diseases 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 4
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 3
- 206010000060 Abdominal distension Diseases 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims description 3
- 239000001775 zeaxanthin Substances 0.000 claims description 3
- 229940043269 zeaxanthin Drugs 0.000 claims description 3
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 claims description 2
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 2
- 239000011774 beta-cryptoxanthin Substances 0.000 claims description 2
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 230000008133 cognitive development Effects 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 235000011649 selenium Nutrition 0.000 claims description 2
- 230000004304 visual acuity Effects 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- GZZPOFFXKUVNSW-UHFFFAOYSA-N Dodecenoic acid Natural products OC(=O)CCCCCCCCCC=C GZZPOFFXKUVNSW-UHFFFAOYSA-N 0.000 claims 1
- 241000186869 Lactobacillus salivarius Species 0.000 claims 1
- 241000194020 Streptococcus thermophilus Species 0.000 claims 1
- 240000003243 Thuja occidentalis Species 0.000 claims 1
- 235000008109 Thuja occidentalis Nutrition 0.000 claims 1
- 229940108928 copper Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004232 linoleic acid Drugs 0.000 claims 1
- 235000008935 nutritious Nutrition 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 235000005911 diet Nutrition 0.000 description 11
- 239000013589 supplement Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 235000013350 formula milk Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 241000186604 Lactobacillus reuteri Species 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- -1 ••胡罗素素 Chemical compound 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000828 canola oil Substances 0.000 description 3
- 235000019519 canola oil Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- WDZQZZLBZOMKDG-HZAHKBIYSA-N C(C)N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)CO)CCCCCCCCCC Chemical compound C(C)N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)CO)CCCCCCCCCC WDZQZZLBZOMKDG-HZAHKBIYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010021746 Infantile colic Diseases 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GQWUPMUMQJMORZ-IXRYGLFGSA-N O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GQWUPMUMQJMORZ-IXRYGLFGSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000019904 Raftiline® Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- WNQQFQRHFNVNSP-UHFFFAOYSA-N [Ca].[Fe] Chemical compound [Ca].[Fe] WNQQFQRHFNVNSP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229940043266 rosin Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Pediatric Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Description
201117818 六、發明說明: 【發明所屬之技術領域】 本發明關於一種用於母乳哺育之嬰兒及寵物之包含至少 一種益生菌及至少一種營養素之營養補充組合物。該組合 物係爲了保持完全以母乳哺育嬰兒。本發明之組合物亦用 • 於改善母礼哺育之嬰兒之健康。亦提供一種製備用於母乳 ΐ月嬰兒之營養補充組合物之方法。 【先前技術】 已明確確定應建議所有新生兒接受母乳。若由於藥物或 其他原因而使母親無法母乳哺育時,已開發了試圖與人乳 最接近之嬰兒配方。 但是,即使母親完全以母乳哺育嬰兒時,母乳仍可能缺 乏某些重要的營養素,其取決於外界因素,諸如母親的飲 食、環境、醫學病症等。 已確定哺乳期的婦女更容易缺少特定的營養素而非飲食 月匕里或蛋白質的整體不足。同樣,微量營養素的不足更易 影響母乳組合物及嬰兒的生長及營養狀況。
Lindsay H Allen在 1994年中期之SCN News, 11 中標題 • 為 Maternal micronutrient malnutrition: effects on breast nd infant nutrition and priorities for intervention」的 文早中提及之解決方法為以所需的營養物補充哺乳期母親 的飲食,以調整乳汁組成中微量營養素之含量。 仁疋,此解決方法通常較不方便且較間接。此外,某些 呂養素之母乳濃度難於藉由在哺乳期補充母親飲食而恢 149998.doc 201117818 復。此外,其他有益於嬰兒之成份(諸如益生菌)無法透過 補充母親之飲食而到達嬰兒。在此態樣中,已開發了包含 益生菌之嬰兒補充劑且(例如)可自w〇 2〇〇7/142596中已 知。 目前已發現在不藉助傳統嬰兒配方的情況下,藉由補充 母乳自身’對嬰兒及母體皆可產生諸多益處。 【發明内容】 因此,本發明之目的係爲了提供一種減輕某些可能發生 在完全由母乳哺育之嬰兒中之不足之補充組合物。在某些 態樣中,本發明補充母乳中某些含量不足之營養素。 藉由獨立之技術方案可解決該目的。附屬技術方案進一 步發展本發明之中心思想。 在第嘘樣中,本發明關於一種用於母乳哺育之嬰兒或 寵物之營養補充組合物,其包含至少一種益生菌及至少一 種選自分別在人體母乳及寵物乳汁中可變性最高的營養素 中之營養素。 ^ 以本發明之組合物於保持完全以母乳哺乳嬰兒上之用途 亦形成本發明之部分。 本發明第三態樣關於一種用於改善母乳哺育之嬰兒之健 康之本發明组合物。 最後’本發明亦關於一種製備用於母乳哺育嬰兒或寵物 之營養補充組合物之方法’其包括以下步驟: -自人體母乳中之可變性最高營養素中選擇至少一 種營養素,及 149998.doc 201117818 -將該至少一種營養素併入營養基質中,形成營養 補充組合物。 【實施方式】 本發明關於一種營養補充組合物。 「補充組合物」意指補充完整的營養飲食之組合物。因 此’該補充組合物不需要提供完整的、均衡的營養飲食。 該組合物係供於母乳哺育之嬰兒或寵物。「嬰兒」意指〇 月至4歲,通常〇月至18個月之嬰孩。本發明之相似及擴展 概念可應用於寵物,諸如(例如)貓及狗。 該組合物較佳針對完全以母乳哺育之嬰兒。「完全母乳 哺月」思指嬰兒之全部能量需求(碳水化合物、蛋白質及 月曰肪)元全由母乳獲得。此等嬰兒不會由嬰兒配方或其他 飲食之非母乳組分獲得的多種營養素之補充中獲益。因 此,藉由適當的補充以彌補人體母乳之可變性(特定言之 人體母乳中最易變之營養素)對於此等「完全以母乳哺育 之嬰兒」至關重要。在其他實施例中,以相同的原則擴 展’本發明係針對自人體母乳中接受5〇%或更多,或 或更多之曰常熱量飲食之嬰兒。 本發明補充組合物較佳提供大於0至50 Kcal/天之間,較 佳1至20 Kcal/天之間’更佳2至1〇 Kcai/天之間之熱量。 本發明補充組合物可提供〇至6 g/天之間,較佳〇 〇1至3 g/天之間,更佳0.05至〇 6 g/天之間之脂肪量。 本發明補充組合物可提供〇至4 g/天之間,較佳〇 〇1至2 g/天之間,更佳〇.02至〇4 g/天之間之碳水化合物量。 149998.doc 201117818 通常’該補充組合物提供小於1.5 g/100 kcal,或小於i g/1〇〇 kcal,較佳小於0.5 g/100 kcal之蛋白質量。 該組合物較佳不包含任何蛋白質。但是,在一實施例 中,該組合物包含肽,較佳2至25個胺基酸長度之小型 肽’及/或不含胺基酸。 本發明組合物可具有大於5 g脂肪/丨〇〇 kca卜較佳大於8 g脂肪/100 kcal ’更佳大於10或15 g/1〇〇 kcal之脂肪值。在 一實施例中’脂肪含量占組合物熱量值之5〇0/〇以上或8〇% 以上。此兩脂肪含量主要源自油性基質。 或者’本發明可具有小於1 g脂肪/100 kcal,較佳小於 0.5 g脂肪/1〇〇 kcal之脂肪值。 在一實施例中,該組合物之熱量密度遠高於一般嬰兒配 方之熱罝密度(因此本發明係一種包含(例如)油性基質(高 熱量)之補充劑)。在一實施例中,該組合物之熱量密度遠 低於一般嬰兒配方之熱量密度(因此本發明係一種具有低 熱量密度但高度相關營養素含量之補充劑)。在一實施例 中’熱量密度係1.3 kcal/g或更少,1 kcal/g組合物或更 少’ 0.5 kcal/g組合物或更少,0.25 kcal/g組合物或更少。 在一實施例中(液體組合物)’該組合物之熱量密度係1 5 1^&1/1111或更多’3 1^31/1111或更多,或5。31/1111或更多。 該組合物較佳係非乳製品。在一實施例中,該組合物實 質上係不含赂蛋白及/或乳清蛋白(各小於5 %,小於1 %或小 於 0_1〇/〇)。 因此本發明組合物本身與趨於為嬰兒提供完整的、均衡 149998.doc 201117818 的營養飲食之嬰兒配方不同,在此態樣中,本發明組合物 係用作母乳之補充劑。 根據本發明,該組合物包含至少一種益生菌及至少一種 選自人體母乳中之可變性最高的營養素中之營養素。 「人體母乳中可變性最高之營養素」意指當比較女性群 體中之母乳組成時,在母乳令變化最多之營養素。特定古 之,某些科學文章描述母乳中最易變之營養素(例如,參 見「Mate窗1 micronutrient malnutrhi〇n 他山⑽ ^如 milk and infant nutrition and priorities for intervention, 3 藉由 Lindsay H Allen等人,SCN N。u,i994,聯」合 國,協調行政委員會,營養小組委員會)。 藉由篩選人體母乳中可變性最高之營養素,本發明組合 物最好可彌補母乳中出現的不足。㈣,可製備更有效: 通节’此等營養素係選自維生素、維生素原、類胡蘿葡 素、多不飽和脂肪酸、長鏈多不飽和脂肪酸、礦物質及胺 基酸。在特定實施例中,此等營養素亦可包括肽。 因此’該營養素可選自以下任何物質:二十二碳六烯酸 (DHA)、α-次亞麻油酸、類胡蘿葡細如,番茄紅素、葉 黃素、广胡蘿萄素、β•胡蘿萄素、β隱黃質、玉米黃質): 鈣鐵、鋅、鋼、峨、石西、硫胺素、核黃素、維生素Β6、 維生素m2、葉酸、維生素c、維生素D、維生素Α、花生 四烯酸或其任何混合物。 在本發明較佳實施例中,該營養素係二十二碳六稀酸 149998.doc 201117818 (DHA)及α-次亞麻油酸,視需要與類胡蘿蔔素之混合物。 本發明組合物進一步包含至少一種益生菌。益生菌可定 義為藉由改良腸道微生物的平衡而對宿主動物具有正面影 響之活的微生物膳食補充劑。藉由本發明選擇的益生微生 物可包括任何選自以下組成之群之益生菌:雙叉桿菌屬 (Bifidobacterium)、乳桿菌屬(Lactobacillus)、鏈球菌 (Streptococcus)、腸球菌(Enterococcus)及酵母菌屬 (Saccharomyces)或其混合物,較佳選自由以下組成之群: 龍根雙叉桿菌(万(/Vi/oZmcieWww /owgwm)、雷特氏雙叉桿菌 (Bifidobacterium lactis)、4 酸乳桿儀(Lactobacillus acidophilus)、鼠李糖乳酸桿菌(Zacio 办 r/mmwosw·?)、副乾赂乳桿菌paracasei)、約 氏乳桿菌/o/msom'z·)、胚芽乳桿菌 (Lactobacillus plantarum)、嗜浪乳得後(Lactobacillus ίβ/ζ·ναη·ί^)、羅伊氏乳桿菌(Zaciokcz7/w·? rewierz·)、屎腸球 菌(Sw/erococcwj 、键球菌(<S7〜piococcws ·?/?)及保 拉第酵母菌(Sacc/zaromyce·? 或其混合物。該益生 菌更佳係選自由以下組成之群:鼠李糖乳酸桿菌CGMCC 1.3724(俗稱 NCC4007 及 LPR)、特別售自丹麥 Christian Hansen公司之商標Bbl2之雷特氏雙叉桿菌CNCM 1-3446 (俗稱NCC2818)、售自曰本森永乳業(Morinaga Milk Industry Co. Ltd.)之商標為BB536之龍根雙叉桿菌ATCC BAA-999、副乾酪乳桿菌CNCM 1-2116(俗稱NCC2461及 ST11)、約氏乳桿菌 CNCM 1-1225(俗稱 NCC533 及 Lai)、售 149998.doc 201117818 自Probiomics(澳大利亞)之商標為PCC之發酵乳桿菌 {Lactobacillus fermentum)VRl 003、龍根雙叉桿菌 CNCM 1-2170、龍根雙叉桿菌CNCM 1-2618、售自Danisco (丹麥) 之商標為Bb-03之短型雙叉桿菌0reve)、 售自曰本森永之商標為M-16V之短型雙叉桿菌、及售自 Institut Rosell (Lallemand)(加拿大)之商標為R〇〇7〇 之短型 雙叉桿菌菌株、副乾酪乳桿菌CNCM 1-1292、特別由Valio 〇y(芬蘭)獲得的商標為LGG之鼠李糖乳酸桿菌ATCC 53103、屎腸球菌SF 68及其混合物。較佳的益生菌係鼠李 糖乳酸桿菌CGMCC 1.3724。另一較佳的益生菌係羅伊氏 乳桿菌’尤其羅伊氏乳桿菌ATCC 55730、ATCC PTA 6 4 7 5、AT C C P T A 4 6 5 9 及 AT C C P T A 5 2 8 9,及更特別係羅 伊氏乳桿菌入丁〇〇 55730及由6丨〇〇&丨3入3獲得的羅伊氏乳桿 菌 DSM 17938(Kungsbroplan 3A Stockholm,瑞典)。 該組合物較佳提供益生菌數量等於1〇3至1〇io cfu/g組合 物(cfll=菌落形成單位)或1〇3至1〇10 cfu/天之間。此表示法 包括該細菌可能係活的、失活或死亡或甚至呈碎片(諸如 DNA或細胞壁材料)存在。換言之,該配方包含的細菌量 係以假設所有細菌均為活菌時之細菌的菌落形成能力表 不,而不論其等事實上是否係活的 '失活或死亡、片斷或 任何混合物或所有此等狀態^該組合物提供益生菌之較佳 數量等於104至1〇9 cfu/g組合物或1〇4至1〇9 cfu/天之間,更 佳數量等於106至108 cfu/g組合物或1〇6至1〇8 cfu/天之間。 因此,根據本發明較佳的組合物包含羅伊氏乳桿菌、二 149998.doc 5 201117818 十二碳六稀酸(DHA)及α-次亞麻油酸。 本發明組合物t之營養素較佳含量為占組合物之〇 〇1% 至10%(w/w),及/或可提供1〇%至ι〇〇%之間之建議曰劑 里。更特疋s之,組合物中之維生素含量可針對嬰兒及目 標年齡之兒童傳送5%至100%之間,較佳2〇%及8〇%之間之 建議日劑量。 該組合物可包含脂質來源’較佳為多不飽和脂肪酸 (PUFA)。該脂質來源可係任何適用於嬰兒配方之脂質或脂 肪。較佳的脂肪來源包括低芥酸菜籽油、大豆油、單細胞 油、魚油、MCT油、棕櫚油精、高油酸葵花油、葵花油及 高油酸紅花油。組合物中可包含必需脂肪酸亞油酸及心次 亞麻油酸。總之,脂肪含量較佳提供補充劑總能量之3〇至 100°/。之間。脂肪來源之η·6與n-3脂肪酸之比率較佳為約 1:2 0至約1 5:1 ;例如約1:1至約1 〇: 1。 多不飽和脂肪酸(PUFA)之含量可提供〇至2〇〇 mg/天,更 佳10至100 mg/天,甚至更佳2〇至65 mg/天之間之劑量。 本發明組合物可進一步包含至少一種益生質(prebi〇_ tic)。益生質可定義為可由選擇性刺激結腸中一種或有限 數量細菌之生長及/或活性而有利地影響宿主,且因此改 良伯主健康之不可消化之食物成份。 益生質可選自N-乙醯化寡糖、中性寡糖或酸性寡糖或其 任何混合物。 Ν·乙醯化寡糖之特徵為存在N-乙醯基殘基,且包括N-乙 醯基-乳糖胺、Ν-乙醯基-胺基半乳糖基葡萄糖及沐乙醯基_ 149998.doc •10· 201117818 半乳糖基乳糖。 中性寡糖係不具有電荷之寡糖。除N-乙醯化寡糖外,中 性寡糖之實例包括半乳寡糖、果寡糖及岩藻寡糖(例如岩 藻乳糖、岩藻糖基化乳糖胺-乳糖等)。該中性寡糖較佳包 括β-半乳寡糖(β-GOS)。 酸性寡糖係彼等具有電荷者。較佳的酸性寡糖包括唾液 酸化的寡糖。此等之特徵為一或多個Ν-乙醯基神經胺酸殘 基,諸如3’-及6’-唾液酸半乳糖(SL)及唾液酸化-乳糖-Ν-四 碳糖。其他的酸性寡糖包括彼等含有糖醛酸殘基者。 在一實施例中,益生質較佳選自人乳寡糖。該人乳寡糖 較佳係選自唾液酸化的寡糖、岩藻糖基化的寡糖或其任何 混合物。 益生質之實施例較佳包含由葡萄糖、半乳糖、木糖、麥 芽糖、蔗糖、乳糖、澱粉、木聚糖、半纖維素、菊糖或其 混合物製成之寡糖。該寡糖更佳包含果寡糖。該益生質最 佳包含果寡糖及菊糖之混合物。此混合物較佳包含 PREBI01® 或購自 RAFTILOSE® 與 RAFTILINE® 之商品混 合物。 益生質之實施例較佳包含約50%至約90%之果寡糖。其 更佳包含約60%至約80%之果寡糖。其最佳包含約70%果 寡糖。 益生質之實施例較佳包含約10%至約50%之菊糖。其更 佳包含約20%至約40%之菊糖。其最佳包含約30°/。之菊 糖。 149998.doc 201117818 當使用時,本發明組合物中之益生質含量可提供01至7 g/天,較佳0.2至6 g/天,特別佳0.5至3 g/天之劑量。 本發明組合物可呈滴劑、凝膠、乳霜、粉末等形式。 在一實施例中’該組合物在室溫下係呈液體形式。其可 包含液體油性基質。該液體油性基質同時作為組合物之栽 劑及作為可使益生菌較好保存之基質。該油性基質可包含 三酸甘油酯,較佳中鏈三酸甘油酯。該油性基質係食品級 油或食品級油之混合物,並可包含低芥酸菜籽油、大豆 油、單細胞油、魚油、棕櫚油、高油酸葵花油及/或葵花 油。該油性基質之含量可占總組合物之5〇%或更多,7〇% 或更多’ 90%或更多,95%或更多。 當組合物係呈乾燥粉末形式時,可提供5〇 1〇§至12 g/天 之間,較佳0.2 g至5 g/天之間之組合物。 當組合物係呈液體形式時,可提供〇〇5 1^至6 天之 間,較佳0.2 ml至3 ml/天之間之組合物。 可依任何合適方法製備本發明組合物。例如,可呈乾燥 形式共同混合營養素’並懸浮於油性基f中。可添加經冷 凉·乾燥或喷霧乾燥的益生菌。 右希望製備液體組合物,將混合物裝入合適的容器中, 較佳在無菌下。在—實施例中,該组合物亦可在容器中乾 /乂佳在加人益生菌前1於進行此裝填類型之合適裝 置可自商品購得。該液體組合物可呈即食組合物形式或呈 濃縮液形式。該濃縮液亦可直接投與嬰兒,取決 劑量》 幻 149998.doc 201117818 若耑要製備叙束組合物時,較佳將液體混合物轉移至合 適的乾燥裝置(諸如噴霧乾燥機或冷;東乾燥機)並轉換為粉 末。該粉末應具有小於約5重量%之含水量。 右組合物係粉末,其較佳在投與嬰兒前先沖泡成液體 中。 本心明組合物顯現以τ優點:其確保補充可能在人體母 乳中變化之營養素。 此外’由於存在益生菌,亦發現諸多益處。與在本組合 物中所存在益生菌相關之益處包括控制或預防絞痛 (C〇hC),減少反胃,改善腸螺動、腹脹、腸痛及通過腸道 (mtestmal transit),減少便秘、腹瀉、感染及過敏,改善 免疫力及睡眠,預防日後發炎。 亦已發現,由於本組合物中存在營養素,加強了益生菌 的作用。J3此’本組合物可獲得所存在的益生菌與營養素 之間之協同作用。例如,可藉由所存在之營養素加強組合 物中益生菌之安定性。或者可藉由協同作用加強益生菌及/ 或營養素之生物可利用性。 組合物可依單次劑量單位遞送至嬰兒。此具有保持安定 性及防止組合物污染之優點。 在一實施例t,本發明關於—種維持完全以母乳哺育嬰 兒之方法’其藉由以根據本發明之組合物哺育該等嬰兒。 因此,本發明組合物可以每天投與嬰兒至少—次。其亦 可在每次哺乳時及/或哺乳之間投與。 、 本發明之一個實施例係關於本文所述之組合物於保持完 149998.doc 201117818 全母乳哺育嬰兒之用途。因此,使用本發明組合物之優點 係嬰兒+需要任何其他食物來源(諸如嬰兒配方)以滿足其 飲食需求。此對母親亦有經濟優勢。 本發明組合物亦可用在改善母乳哺f之嬰兒或寵物(諸 如貓或狗)之健康之方法中。因此,根據本發明組合物用 於改善母乳哺育嬰兒之健康形成本發明之一部分。 健康之改善係由降低或預防營養不足及絞痛,減少反 胃,減少過敏’減少特應性疾病,抵抗感染,改善認知發 展’改善腸成熟,改善腸螺動,減少腹脹及腸痛,改善通 過腸道,預防或減少便秘及腹寫,改善新生兒免疫力,提 高日後免疫力’控制脂肪形成,預防日後超重,預防日後 發炎’改善睡眠模式’改善視力敏度等而達到。 爲了改善母乳哺育嬰兒之健康,該組合物較佳每日投盘 該嬰兒。 種製備用於母乳哺育嬰兒 在本發明另一態樣中,提供一 之營養補充組合物之方法。 該方法之第-步驟包括自人體母乳中之最易變之營養素 中篩選至少一種營養素。 此點很4易由熟f此項技術者比較女性群體之間之人體 母乳組成’並篩選變化最多之營養素即可達成。 至少-種營養素較佳選自維生素、維生素原、類胡蘿萄 素、多f飽和脂肪酸、礦物質、胺基酸。在特定實施例 中,此等營養素亦可包括肽。 因此, 營養素可選自 以下任何物質:二十二碳六烯酸 149998.doc -14* 201117818 (DHA)、α-次亞麻油酸、類胡蘿蔔专㈠ 果(例如,番茄紅素、 黃素、α-胡蘿蔔素、β-胡蘿蔔素、β拿主 一 Ρ丨急汽質、玉米黃質)、 鈣、鐵、辞、銅、碘、硒、硫胺素、枯 孩汽素、维生素Β6、 維生素Β12、葉酸、維生素C、維生夸 H常D、维生素Α、花生 四烯酸、或其任何混合物。 然後將該營養素併入營養基質中,形成營養補充組合 物。此係藉由此項技術令常用的方法進行。 營養基質」意指可食用的基質。該基質可包含任何油 類、奶粉或構成基質之成份。 因此,所產生的營養補充組合物富含至少一種特定營養 素且提供以下優點:其可用於完全以母乳哺育之嬰兒中, 以彌補可能的營養素之不足。 在較佳實施例中,藉由本發明之方法獲得的營養補充組 合物進一步包含益生菌。該益生菌可係任何本申請案中描 述之彼等。 藉由以下非限制性實例進一步闡述本發明。 實例 於油性基質中製備具有以下特定營養素之組合物。該油 性基質係習知用於嬰兒之食用油。建議日劑量係1 ml。 _組合物中各成份之量: U羅伊氏乳桿菌DSM 17938 : 108 cfu/日劑量
2) DHA: 2〇 mg:十二碳六烯酸(即 50 mg DHASCO 油)/曰劑量。 3) ALA : 45 mg α•次亞麻油酸(即500 mg菜籽油 149998.doc • 15· 201117818 (canola oil)(低芬酸菜耔油))/曰劑量。 4)類胡蘿蔔素:每曰劑量: -葉黃素:2.8微克 -β-胡蘿蔔素:1.6微克 -番茄红素:1.6微克 在以下公開案中之嬰兒配方中闡述益生菌羅伊氏乳桿菌 之效用:l)Savino等人說明之抗絞痛作用「Savino F,Pelle E, Palumeri E, Oggero R, Miniero R. 2006. Lactobacillus reuteri(美國標準菌種中心(American Type Culture Collection Strain)55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007 Jan;119(l):el24-30」;2)Indrio等人說明之改善胃腸道 螺動及便秘,「Indrio F,Riezzo G,Raimondi F,Bisceglia M, Cavallo L, Francavilla R. 2008. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatrics 152: 801-6」。 149998.doc 16-
Claims (1)
- 201117818 七、申請專利範圍: 1· 一種用於母乳哺育嬰兒或寵.物之營養補充組合物,其包 含至少-種益生菌及至少一種營養素選自人類母乳’中: 可變之營養素。 • 2.如請求項1之組合物,其中該營養素係選自維生素、維 , 生素原、類胡蘿蔔素、多不飽和脂肪酸、長鏈多不飽和 脂肪酸、礦物質、胺基酸、肽或其任何混合物。 3_如請求項〖或2之組合物,其中該營養素係以下任何物 質.—十二碳六烯酸(DHA)、花生四烯酸(ARA)、α·次亞 麻油酸、類胡蘿葡素(諸如番茄紅素、葉黃素、α_胡蘿爵 素' β-胡蘿蔔素、β-隱黃質、玉米黃質)、鈣、鐵、鋅' 銅、碘、硒、硫胺素、核黃素、維生素B6、維生素 Β12、葉酸、維生素C、維生素D、維生素Α、或其任何 混合物。 4_如請求項1或2之組合物’其中該等營養素包含二十二碳 六烯酸及α-次亞麻油酸’視需要與類胡蘿萄素之混合 物。 5.如請求項1或2之組合物’其中益生菌係選自乳桿菌屬 (lactobacillus)、雙又桿菌屬(bifidobacterium)、腸球菌屬 (Enterococcus)、酵母菌屬(Saccharomyces)或鍵球菌屬 - (Streptococcus),較佳選自鼠李糖乳酸桿菌 、副乾酷乳桿菌(Zaciok-cillus paracasei) > 羅伊氏乳桿菌{Lactobacillus rewkW)、嗜酸乳桿菌 acidophilus)、约氏 149998.doc 201117818 乳桿菌、胚芽乳桿菌 (Lactobacillus plantarum)、嘴液乳禪溘(Lactobacillus salivarius)、嗜叛繞珠蛰(Streptococcus thermophilus)、 龍根雙叉桿菌/o«gwm)、雷特氏雙又桿 窗、Bifidobacterium /ac"\s)、屎腸球菌(五价er〇c〇CCWi /aecz'Mm)、鏈球菌(々repbcoccwi印)及保拉第酵母菌 (iSaccAarowyces 6〇M/ans?z7)或其任何混合物。 6.如請求項1或2之組合物,其包含至少一種益生質(prebi〇_ tic) ’較佳選自人乳寡糖,更佳選自唾液酸化之寡糖、 岩藻糖基化寡糖或其任何混合物。 7·如請求項1或2之組合物’其中該組合物係呈液滴劑、凝 膠、乳霜、粉末形式。 8. 如請求項1或2之組合物,其中該益生菌之含量可提供每 曰劑量103至1〇10 cfu/天之間,較佳1〇4至1〇9 cfu/天之 間’更佳106及108cfu/天之間。 9. 如清求項1或2之組合物,其中至少一種營養素之含量可 提供嬰兒及目標年齡兒童之建議每曰劑量之5至ι〇〇%之 間較佳1 〇%至80%之間’更佳20%至50%之間。 10. 如吻求項1或2之組合物,其具有熱量密度6 5 kcai/g或更 多,較佳9 kcal/g或更多,最佳30 kcai/g或更多,或j 5 或3kcal/ml或更多’或5或7kcal/ml或更多。 11. 如吻求項1或2之組合物,其提供蛋白量劑量小於1 5以 100 kcal,或小於 1 g/i〇〇 kcai ,較佳小於 〇 5 g/i〇〇 kcal 〇 149998.doc 201117818 12_如請求項1或2之組合物,其具有脂肪值大於$ g脂肪/1〇〇 kcal ’較佳大於8 g脂肪/100 kca卜或更佳大於1〇或15 g 月曰肪/1〇〇 keal。 13_如請求項丨或2之組合物,其中脂肪含量占組合物熱量值 之50%以上或8〇%以上。 14·如請求項1或2之組合物,其具有脂肪值小於1 g脂肪/1〇〇 kcal ’較佳小於〇.5 g脂肪/1〇〇 kcal。 15. —種如請求項丨至丨4中任一項之組合物之用途,其用於 保持完全以母乳哺育嬰兒。 16. 如請求項丨或2之組合物,其用於改善母乳哺育嬰兒之健 康。 17.如請求項16之組合物,其中健康之改善係藉由降低或預 防S養不足,減少或預防絞痛(c〇hcs),減少反胃,減少 過敏,減少特應性(at〇pic)疾病,抵抗感染,改善認知發 展,改善腸成熟,改善腸蠕動,減少腹脹及腸痛,改善 通過腸道(intestinal transit),預防或減少便秘及腹瀉, 改善新生兒免疫力,提高日後免疫力控制脂肪形成, 預防日後超重,預防日後發炎,改善睡眠模式,改善視 力敏度而達到。 1S.如呀求項1或2之組合物,其中該組合物係每日投與母乳 哺育之嬰兒。 19,種製備供母乳哺育之嬰兒或寵物用之營養補充組合物 之方法,其包括以下步驟: 少一種營養 人類母乳中最 149998.doc 201117818 素,及 將該至少一種營養素併入營養基質中,形成營養補充 組合物。 20.如請求項19之方法,其中該營養補充組合物包含益生 菌。 149998.doc 201117818 四、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 五、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) 149998.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09166969 | 2009-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201117818A true TW201117818A (en) | 2011-06-01 |
Family
ID=41259077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099125518A TW201117818A (en) | 2009-07-31 | 2010-07-30 | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120121562A1 (zh) |
EP (1) | EP2459202A1 (zh) |
CN (1) | CN102481323A (zh) |
AU (1) | AU2010277582A1 (zh) |
BR (1) | BR112012002223A2 (zh) |
CA (1) | CA2767960A1 (zh) |
CL (1) | CL2012000234A1 (zh) |
IN (1) | IN2012DN00282A (zh) |
MX (1) | MX2012001362A (zh) |
RU (1) | RU2012107695A (zh) |
SG (1) | SG177541A1 (zh) |
TW (1) | TW201117818A (zh) |
WO (1) | WO2011012655A1 (zh) |
ZA (1) | ZA201201471B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
NZ612472A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
MX338174B (es) | 2010-12-31 | 2016-04-06 | Abbott Lab | Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios. |
MY166945A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
NZ612455A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
CN103391783A (zh) | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
CN102106463B (zh) * | 2011-01-31 | 2012-12-05 | 杨永浩 | 一种微生物饲料添加剂及其制备方法 |
WO2012107865A2 (en) * | 2011-02-10 | 2012-08-16 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
ITMI20111488A1 (it) * | 2011-08-03 | 2013-02-04 | Gnosis Spa | Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita' |
SG2014013478A (en) | 2011-08-29 | 2014-05-29 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US20140271562A1 (en) * | 2011-10-18 | 2014-09-18 | Nestec S.A. | Composition for use in brain growth and/or cognitive and/or psychomotor development |
BR112014008425A2 (pt) * | 2011-10-18 | 2017-04-11 | Nestec Sa | composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal |
KR101166798B1 (ko) * | 2011-12-19 | 2012-07-26 | 김대현 | 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물 |
UA118339C2 (uk) * | 2012-09-03 | 2019-01-10 | Біогайа Аб | Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти) |
US9987306B2 (en) | 2012-10-15 | 2018-06-05 | University Of Florida Research Foundation, Inc. | Materials and methods for prevention and treatment of diarrhea and inflammation in the gastrointestinal tract |
US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
CA2942555A1 (en) | 2014-03-26 | 2015-10-01 | Abbott Laboratories | Nutritional supplement powder |
WO2015176229A1 (en) * | 2014-05-20 | 2015-11-26 | Nestle (China) Ltd. | Delivery mode specific synthetic nutritional compositions and nutritional systems comprising them |
US10821124B2 (en) * | 2015-03-05 | 2020-11-03 | Societe Des Produits Nestle S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
CN105030843A (zh) * | 2015-06-18 | 2015-11-11 | 陈英扬 | 罗伊氏乳杆菌滴剂及其制备方法 |
CA2994347A1 (en) * | 2015-08-31 | 2017-03-09 | Nestec S.A. | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances |
ES2971165T3 (es) | 2015-12-14 | 2024-06-03 | Nestle Sa | Composición nutricional y preparado para lactantes para estimular la mielinización de novo |
US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
WO2017151540A1 (en) | 2016-02-29 | 2017-09-08 | Abbott Laboratories | Nutritional supplement powder |
KR101938865B1 (ko) * | 2016-11-03 | 2019-01-16 | 주식회사 쎌바이오텍 | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
RU2019141902A (ru) * | 2017-05-24 | 2021-06-17 | Сосьете Де Продюи Нестле С.А. | Композиция, содержащая олигофруктозу (of), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ |
WO2019002607A1 (en) * | 2017-06-30 | 2019-01-03 | N.V. Nutricia | SYMBIOTIC COMPOSITION FOR THE PREVENTION OF DISORDERS |
EP3672600A4 (en) | 2017-08-21 | 2021-05-19 | Glycom A/S | SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS |
CN108823125A (zh) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | 一种治疗睡眠障碍益生菌制剂的生产方法及应用 |
WO2020033708A1 (en) * | 2018-08-08 | 2020-02-13 | Mars, Incorporated | Pet food products comprising oligosaccharides and methods of use |
CN113660941A (zh) * | 2018-12-21 | 2021-11-16 | 雀巢产品有限公司 | 用于治疗***反应性疾病的益生菌组合 |
US20210352925A1 (en) * | 2019-02-04 | 2021-11-18 | N.V. Nutricia | Fermented formula with non digestible oligosaccharides for sleep improvement |
KR102188765B1 (ko) * | 2019-06-12 | 2020-12-08 | 정옥숙 | 애완동물용 동결건조파우더 및 이의 제조방법 |
WO2021105353A1 (en) * | 2019-11-29 | 2021-06-03 | Société des Produits Nestlé S.A. | Compositions and methods with a probiotic and a nutrient and/or mineral for the prevention or treatment of mastitis |
CN112868800A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 含母乳低聚糖提高免疫力的婴幼儿配方奶粉及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3936799C1 (zh) * | 1989-11-04 | 1991-01-10 | Deutsche Atochem Werke Gmbh, 5300 Bonn, De | |
FR2714574B1 (fr) * | 1993-12-31 | 1996-03-15 | Inst Rech Biolog Sa | Nouveaux suppléments alimentaires pour la nutrition des très jeunes enfants. |
US7033629B2 (en) * | 2001-08-31 | 2006-04-25 | Nutricopia Inc. | Nutritional frozen dessert and methods of manufacture |
ES2355382T3 (es) * | 2003-06-23 | 2011-03-25 | Nestec S.A. | Fórmula para lactantes o de continuación. |
US20070031537A1 (en) * | 2003-06-23 | 2007-02-08 | Marie-Cristene Secretin | Infant or follow-on formula |
AU2004279621A1 (en) * | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
US20060194241A1 (en) * | 2005-02-28 | 2006-08-31 | Jan Knol | Lactobacillus specific probes |
US20060251634A1 (en) * | 2005-05-06 | 2006-11-09 | Ho-Jin Kang | Method of improving immune function in mammals using lactobacillus strains with certain lipids |
US20070059297A1 (en) * | 2005-08-04 | 2007-03-15 | Nestec, S.A. | Methods and compositions for improving visual acuity |
PL1940248T3 (pl) * | 2005-10-05 | 2010-05-31 | Nestec Sa | Zastosowanie odżywczej formulacji do promowania doganiania wzrostu |
PL2004201T3 (pl) * | 2006-03-29 | 2019-02-28 | Nestec S.A. | Suplementy diety zawierające probiotyki |
US7374924B2 (en) | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
NL1033521C2 (nl) * | 2007-03-08 | 2008-09-09 | Friesland Brands Bv | Kindervoedingen met geoptimaliseerde aminozuursamenstelling. |
EP1974734A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
EP1974743A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
US20090118228A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
EP2219639A1 (en) * | 2007-12-17 | 2010-08-25 | University of Florida Research Foundation, Inc. | Materials and methods for treatment of pathological ocular vascular proliferation |
EP2344148B2 (en) * | 2008-09-19 | 2024-05-08 | Société des Produits Nestlé S.A. | Nutritional support to prevent or moderate bone marrow paralysis during anti-cancer treatment |
-
2010
- 2010-07-28 CA CA2767960A patent/CA2767960A1/en not_active Abandoned
- 2010-07-28 US US13/387,405 patent/US20120121562A1/en not_active Abandoned
- 2010-07-28 AU AU2010277582A patent/AU2010277582A1/en not_active Abandoned
- 2010-07-28 MX MX2012001362A patent/MX2012001362A/es not_active Application Discontinuation
- 2010-07-28 SG SG2012001038A patent/SG177541A1/en unknown
- 2010-07-28 IN IN282DEN2012 patent/IN2012DN00282A/en unknown
- 2010-07-28 CN CN2010800334746A patent/CN102481323A/zh active Pending
- 2010-07-28 BR BR112012002223A patent/BR112012002223A2/pt not_active IP Right Cessation
- 2010-07-28 WO PCT/EP2010/060973 patent/WO2011012655A1/en active Application Filing
- 2010-07-28 EP EP10740200A patent/EP2459202A1/en not_active Withdrawn
- 2010-07-28 RU RU2012107695/10A patent/RU2012107695A/ru not_active Application Discontinuation
- 2010-07-30 TW TW099125518A patent/TW201117818A/zh unknown
-
2012
- 2012-01-30 CL CL2012000234A patent/CL2012000234A1/es unknown
- 2012-02-28 ZA ZA2012/01471A patent/ZA201201471B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201201471B (en) | 2014-08-27 |
CA2767960A1 (en) | 2011-02-03 |
MX2012001362A (es) | 2012-02-22 |
SG177541A1 (en) | 2012-02-28 |
CL2012000234A1 (es) | 2012-09-28 |
US20120121562A1 (en) | 2012-05-17 |
WO2011012655A1 (en) | 2011-02-03 |
BR112012002223A2 (pt) | 2016-06-07 |
IN2012DN00282A (zh) | 2015-05-08 |
AU2010277582A1 (en) | 2012-02-02 |
RU2012107695A (ru) | 2013-09-10 |
CN102481323A (zh) | 2012-05-30 |
EP2459202A1 (en) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201117818A (en) | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients | |
AU2018205143B2 (en) | Use of nutritional compositions having a low protein amount | |
RU2570473C2 (ru) | Комплект питательных смесей с пробиотиками, созданных с учетом возраста | |
RU2521500C2 (ru) | ПРИМЕНЕНИЕ ШТАММА Bifidobacterium lactis CNCM I-3446 У ДЕТЕЙ РОЖДЕННЫХ, ПУТЕМ КЕСАРЕВА СЕЧЕНИЯ (ВАРИАНТЫ) И ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННЫЙ ШТАММ (ВАРИАНТЫ) | |
AU2007216461B2 (en) | Use of bifidobacterium longum for the prevention and treatment of inflammation | |
RU2543815C2 (ru) | Питательные композиции, содержащие лактоферрин и пробиотики, и наборы из их частей | |
AU2018206853B2 (en) | Liquid milk fortifier composition with relatively high lipid content | |
TW201225858A (en) | Array of complementary infant/young child nutritional compositions | |
AU2009268209A1 (en) | A nutritional composition with free amino acids and structured lipids | |
RU2565728C2 (ru) | Комплект учитывающих возрастные особенности питательных смесей с оптимальным содержанием жира | |
AU2014356449B2 (en) | Age-tailored nutritional compositions with a varying protein content | |
AU2014361231B2 (en) | An age-tailored nutrition system for an infant | |
AU2014361231A1 (en) | An age-tailored nutrition system for an infant | |
AU2014361228A1 (en) | Array of age-tailored nutritional formulae with optimum mineral nutrient content | |
Shirsath et al. | Role of Food Supplements in Gut Health | |
TW201130429A (en) | Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof | |
TW201304695A (zh) | 一系列依年齡特製之含有益生菌之營養配方 |